Investigating the neuroprotective potential of repaglinide and development of novel pegylated nanocarriers for the management of metabolic disorder linked Alzheimer’s disease
JavaScript is disabled for your browser. Some features of this site may not work without it.
Investigating the neuroprotective potential of repaglinide and development of novel pegylated nanocarriers for the management of metabolic disorder linked Alzheimer’s disease